Dr. Geynisman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Suite N713
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-214-3779
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 2010 - 2013
- UPMC Medical EducationResidency, Internal Medicine, 2006 - 2010
- University of Pittsburgh School of MedicineClass of 2006
Certifications & Licensure
- PA State Medical License 2006 - 2024
- IL State Medical License 2010 - 2014
- American Board of Internal Medicine Medical Oncology
- American Board of Medical OncologyMedical Oncology
Clinical Trials
- A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer Start of enrollment: 2020 Dec 01
Publications & Presentations
PubMed
- 117 citationsTrends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011Ya Chen Tina Shih, Fabrice Smieliauskas, Daniel M. Geynisman, Ronan J. Kelly, Thomas J. Smith
Journal of Clinical Oncology. 2015-05-18 - 15 citationsRole of immunotherapy in localized muscle invasive urothelial cancer.Jasmeet Kaur, Woonyoung Choi, Daniel M. Geynisman, Elizabeth R. Plimack, Pooja Ghatalia
Therapeutic Advances in Medical Oncology. 2021-09-22 - 89 citationsRandomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D. Galsky, Amir Mortazavi, Matthew I. Milowsky, Saby George, Sumati Gupta
Journal of Clinical Oncology. 2020-04-09
Press Mentions
- Daniel M. Geynisman, MD, Named New JNCCN Editor-in-ChiefMay 17th, 2024
- ASCO GU 2023: Update on Bladder-Sparing Treatment Trial: RETAIN BLADDERFebruary 15th, 2023
- Fox Chase Receives Grant to Study Prostate Cancer Patients Being Treated with Androgen Deprivation TherapySeptember 15th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: